HC Wainwright restated their buy rating on shares of Genocea Biosciences (NASDAQ:GNCA) in a research report report published on Monday, AnalystRatings.com reports.
A number of other equities research analysts also recently weighed in on the company. ValuEngine raised Genocea Biosciences from a hold rating to a buy rating in a research report on Friday, November 1st. Needham & Company LLC reissued a buy rating and set a $10.00 target price on shares of Genocea Biosciences in a research report on Thursday, October 24th. Finally, Zacks Investment Research downgraded Genocea Biosciences from a buy rating to a hold rating in a research report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $12.94.
GNCA stock traded up $0.01 during trading on Monday, reaching $2.25. 241,400 shares of the stock were exchanged, compared to its average volume of 297,488. Genocea Biosciences has a twelve month low of $1.99 and a twelve month high of $11.28. The company has a market capitalization of $56.48 million, a P/E ratio of -0.61 and a beta of 2.43. The stock has a 50 day simple moving average of $2.60 and a 200-day simple moving average of $3.16. The company has a current ratio of 4.33, a quick ratio of 4.33 and a debt-to-equity ratio of 0.45.
Genocea Biosciences (NASDAQ:GNCA) last released its earnings results on Thursday, October 24th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.17. Equities analysts predict that Genocea Biosciences will post -1.78 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in GNCA. FNY Investment Advisers LLC lifted its stake in Genocea Biosciences by 88.2% during the third quarter. FNY Investment Advisers LLC now owns 253,000 shares of the biotechnology company’s stock worth $733,000 after purchasing an additional 118,600 shares during the period. Citadel Advisors LLC bought a new position in Genocea Biosciences during the second quarter worth about $68,000. D. E. Shaw & Co. Inc. bought a new position in Genocea Biosciences during the second quarter worth about $84,000. Cubist Systematic Strategies LLC bought a new position in Genocea Biosciences during the second quarter worth about $40,000. Finally, Morgan Stanley bought a new position in Genocea Biosciences during the second quarter worth about $26,000. 56.33% of the stock is currently owned by institutional investors and hedge funds.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
See Also: The risks of owning bonds
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.